HSBC Continental Europe 1 Interim Results 2022
On 29 July 2022, HSBC Continental Europe’s Board of Directors approved the bank’s consolidated financial statements for the first half of 2022.
HSBC Continental Europe’s performance during the first half of 2022 was positive with continued profitability driven by growth in wholesale banking revenues, demonstrating the strength of our global franchise and international connectivity, coupled with low credit losses and a favourable cost performance. With inflationary pressure across Europe and the ongoing Russia-Ukraine war, we expect to be operating in a more difficult environment for the remainder of the year.
Reported consolidated profit before tax was €184m, down from €187m in the first half of 2021, and included an exceptional loss and related impairments of €111m recognised in relation to the planned sale of HSBC Continental Europe’s operations in Greece.
Reported net operating income before change in expected credit losses and other credit impairment charges was €1,218m, down from €1,296m in the first half of 2021, including the exceptional loss recognised in relation to the planned sale of the operations in Greece and a less favourable PVIF movement – €123m in the first half of 2022, compared with a favourable movement of €171m in the first half of 2021. These impacts were largely offset by growth in Commercial Banking and Global Banking, which benefitted from increased client activity and rising interest rates. In addition, Markets and Securities Services revenues increased due to higher transaction volumes, notably in Global Foreign Exchange and Securities Services.
Reported change in expected credit losses and other credit impairment charges was nil, compared to a release of €1m in the first half of 2021. The deterioration of forward-looking economic conditions driven by the rising risk of stagflation and disruption to energy supply was offset by the release of Stage 3 provisions.
Reported operating expenses were €1,034m, down from €1,111m in the first half of 2021. The decrease was due to the recognition of a recovery of VAT paid in 2021 and lower staff costs, partly offset by transformation related costs.
Reported profit attributable to shareholders of the parent company was €127m for the half year to 30 June 2022, compared with €153m in the first half of 2021.
The consolidated balance sheet of HSBC Continental Europe showed total assets of €239bn at 30 June 2022, compared to €223bn at 31 December 2021 with the increase mainly driven by mark-to-market movements on derivatives.
At 30 June 2022, HSBC Continental Europe reported a liquidity coverage ratio (LCR)2 of 145% and a net stable funding ratio (NSFR)3 of 129%. The bank’s fully loaded common equity tier 1 (CET1) ratio was 13.7% and the fully loaded total capital ratio was 18.7% The fully loaded leverage ratio was 3.9%. The solvency ratio of the Life Insurance subsidiary was 263%4.
Planned sale of Greece branch operations and retail banking business in France
Our business transformation has continued to progress at pace, with the signing of a sale and purchase agreement for the sale of our branch operations in Greece to Pancreta Bank SA on 24 May 2022. This followed the completion of the works council consultations. Completion of the potential transaction is subject to regulatory approval and is currently expected to finalise towards the end of the first half of 2023.
As at 30 June 2022, €2.1bn in total assets, including €0.4bn of customer loan balances and €2.3bn in total liabilities, including €2.2bn of customer accounts were reclassified as held for sale in accordance with IFRS 5 and losses and impairments of €111m were recognised for the planned sale of Greece branch operations.
As previously disclosed, we remain on track to complete the sale of our retail banking business in France in the second half of 2023.
Appendix
Interim accounts were subject to a limited review by the statutory auditors.
Summary consolidated income statement
€m | Half year to
|
Half year to
|
Half year to
|
Net interest income | 556 | 480 | 507 |
Net fee income | 485 | 457 | 458 |
Net income/(expense) from financial instruments held for trading or managed on a fair value basis | 211 | 90 | (9) |
Other operating income/(expense) | (34) | 269 | 111 |
Net operating income before change in expected credit losses and other credit impairment charges | 1,218 | 1,296 | 1,067 |
Change in expected credit losses and other credit impairment charges | — | 1 | (34) |
Total operating expenses | (1,034) | (1,111) | (935) |
Share of profit in associates and joint ventures | — | 1 | — |
Profit/(loss) before tax | 184 | 187 | 98 |
Tax expense | (57) | (34) | 17 |
Profit/(loss) for the period | 127 | 153 | 115 |
Profit/(loss) attributable to shareholders of the parent company | 127 | 153 | 116 |
Profit/(loss) attributable to non-controlling interests | — | — | (1) |
PVIF (Present value of in force long-term insurance business)
HSBC Continental Europe, through its HSBC Assurances Vie subsidiary, accounts for its life insurance business using the embedded value method, which provides a comprehensive framework for assessing risk and valuation. PVIF (present value of in force long-term insurance business) is the present value of future profits from existing insurance policies.
The PVIF calculation is based on assumptions that take into account business risks and uncertainties. When projecting cash flows, HSBC Assurances Vie makes a series of assumptions regarding future experience, taking into account local market conditions and management’s judgment of future local trends.
In the first half of 2022, the PVIF movement was favourable by €123m, compared to €171m in the first half of 2021.
Post-balance sheet events
On 20 July 2022, the Board of Directors convened an Extraordinary General Meeting to be held on 2 September 2022 to propose a share capital increase of €1,300m, related to the planned sale of the retail banking business in France.
Alternative performance metrics
To measure our performance, we also use non-GAAP financial measures, including those derived from our reported results that eliminate factors that distort year-on-year comparisons. The ‘adjusted performance’ measure removes the impact of ‘significant items’, listed below, and year-on-year foreign currency translation differences.
€m | Half year to 30 June 2022 | Half year to 30 June 2021 | Half year to 31 Dec 2021 |
Reported revenue | 1,218 | 1,296 | 1,067 |
Significant revenue items | 93 | 26 | 129 |
Adjusted revenue | 1,311 | 1,322 | 1,196 |
Reported operating expenses | (1,034) | (1,111) | (935) |
Significant cost items | 75 | 30 | 61 |
– Impairment of goodwill, intangibles and tangibles | 8 | (1) | 3 |
– Restructuring cost and other significant items | 67 | 31 | 58 |
Adjusted operating expenses | (959) | (1,081) | (874) |
Adjusted results by business line
HSBC Continental Europe changed its segmental reporting in the second half of 2021 by splitting the business line ‘Global Banking and Markets’ into three business lines: ‘Markets and Securities Services’, ‘Global Banking’ and ‘Global Banking and Markets Other’. Financials for the first half of 2021 were re-presented accordingly with no impact on the consolidated financial results.
Wealth and
| Commercial
| Markets and
| Global
| Global Banking
| Corporate
| Total | ||||||||
€m | Half year to 30 June 2022 | |||||||||||||
Net operating income before change in expected credit losses and other credit impairment charges | 467 | 410 | 179 | 251 | 27 | (23) | 1,311 | |||||||
Change in expected credit losses and other credit impairment charges | (2) | 11 | — | (10) | 1 | — | — | |||||||
Total operating expenses | (361) | (215) | (201) | (140) | (31) | (11) | (959) | |||||||
Share of profit in associates and joint ventures | — | — | — | — | — | — | — | |||||||
Adjusted profit/(loss) before tax | 104 | 206 | (22) | 101 | (3) | (34) | 352 | |||||||
Half year to 30 June 2021 | ||||||||||||||
Net operating income before change in expected credit losses and other credit impairment charges | 544 | 363 | 157 | 224 | 30 | 4 | 1,322 | |||||||
Change in expected credit losses and other credit impairment charges | 10 | (33) | — | 24 | — | — | 1 | |||||||
Total operating expenses | (397) | (254) | (230) | (137) | (31) | (32) | (1,081) | |||||||
Share of profit in associates and joint ventures | — | — | — | — | — | 1 | 1 | |||||||
Adjusted profit/(loss) before tax | 157 | 76 | (73) | 111 | (1) | (27) | 243 | |||||||
Half year to 31 December 2021 | ||||||||||||||
Net operating income before change in expected credit losses and other credit impairment charges | 394 | 362 | 103 | 279 | 40 | 18 | 1,196 | |||||||
Change in expected credit losses and other credit impairment charges | 10 | (35) | — | (11) | 2 | — | (34) | |||||||
Total operating expenses | (363) | (181) | (146) | (123) | (33) | (28) | (874) | |||||||
Share of profit in associates and joint ventures | — | — | — | — | — | — | — | |||||||
Adjusted profit/(loss) before tax | 41 | 146 | (43) | 145 | 9 | (10) | 288 |
HSBC Continental Europe
Headquartered in Paris, HSBC Continental Europe is a subsidiary of HSBC Holdings plc. HSBC Continental Europe includes, in addition to its activities in France, the activities of 10 European branches (Belgium, Czech Republic, Greece, Ireland, Italy, Luxembourg, Netherlands, Poland, Spain and Sweden). HSBC Continental Europe’s mission is to serve customers in continental Europe for their needs worldwide and customers in other Group countries for their needs in continental Europe.
HSBC Holdings plc
HSBC Holdings plc, the parent company of HSBC, is headquartered in London. HSBC serves customers worldwide from offices in 63 countries and territories in its geographical regions: Europe, Asia, North America, Latin America, and Middle East and North Africa. With assets of US$2,985bn at 30 June 2022, HSBC is one of the world’s largest banking and financial services organisations.
Disclaimer
This press release contains certain forward-looking statements with respect to the financial condition, results of operations and business of the entity. Statements that are not historical facts, including statements about the entity’s beliefs and expectations, are forward-looking statements. Words such as ‘expects’, ‘anticipates’, ‘intends’, ‘plans’, ‘believes’, ‘seeks’, ‘estimates’, ‘potential’ and ‘reasonably possible’, variations of these words and similar expressions are intended to identify forward-looking statements. These statements are based on current plans, estimates and projections, and therefore undue reliance should not be placed on them. Forward-looking statements speak only as of the date they are made. HSBC Continental Europe makes no commitment to revise or update any forward-looking statements to reflect events or circumstances occurring or existing after the date of any forward-looking statement. Forward-looking statements involve inherent risks and uncertainties. Readers are cautioned that a number of factors could cause actual results to differ, in some instances materially, from those anticipated or implied in any forward-looking statements.
1 HSBC Continental Europe includes, in addition to its activities in France, the activities of 10 European branches (Belgium, Czech Republic, Greece, Ireland, Italy, Luxembourg, Netherlands, Poland, Spain and Sweden)
2 Computed in respect of the EU Delegated act
3 Computed in respect of CRR II (Regulation EU 2019/876)
4 LCR, NSFR and the solvency ratio of the Life Assurance subsidiary are unaudited
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220801005368/en/
Contact information
Raphaële-Marie Hirsch
raphaele.marie.hirsch@hsbc.fr
07 64 57 35 55
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio
Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)
Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release
Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 14:30:00 CEST | Press release
Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new
MEDIA ALERT: Wolters Kluwer expert comments on European Parliament vote to pass amendment implementing Basel III reforms26.4.2024 14:00:00 CEST | Press release
The European financial landscape saw a milestone event this week, as the EU Parliament passed the Amendment to Regulation (EU) No 575/2013, implementing the Basel III finalization within Europe. This monumental step forward comes with the adoption of the Capital Requirements Regulation (CRR3) amendments, which are part of a broader legislative package, including amendments to Directive 2013/36/EU, known as the Capital Requirements Directive or CRD. Jeroen Van Doorsselaere, Vice President of Global Product & Platform Management, Wolters Kluwer FRR, said: “The adoption of the Capital Requirements Regulation (CRR3) amendments represents a landmark change for the banking industry, designed to strengthen the framework for risk-based capital requirements and address ESG risks. “This is a major overhaul of the capital requirements framework, impacting various aspects, including credit risk, operational risk, market risk, and the capital floor. Whereas other significant jurisdictions, includin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom